Tesamorelin GHRH Peptide Boosts Natural Growth Hormone Pulses Without Affecting Insulin Sensitivity

Open-label clinical study in 13 healthy males (mean age 45, mean BMI 27.3). Participants received tesamorelin 2 mg subcutaneously daily for 2 weeks, with assessments at baseline, end of treatment, and after 2 weeks of washout. GH pulsatility was measured via overnight frequent blood sampling. Insulin sensitivity was assessed using the gold-standard euglycemic hyperinsulinemic clamp technique.

People with excess belly fat have reduced growth hormone secretion, which may contribute to metabolic problems. Direct GH replacement can worsen insulin resistance, creating a therapeutic dilemma. Tesamorelin — by stimulating the body's own GH production through its natural pulsatile pattern — offers a potentially safer alternative. This study's demonstration of preserved insulin sensitivity is crucial for the drug's clinical application, particularly in metabolically vulnerable populations.

Tesamorelin was subsequently approved by the FDA for reducing excess abdominal fat in HIV-associated lipodystrophy. This study provides foundational evidence for understanding its mechanism — augmenting natural GH pulsatility rather than simply flooding the system with GH. The preservation of insulin sensitivity distinguishes GHRH-based approaches from direct GH therapy and has important implications for the growing peptide community interested in growth hormone optimization.

Very small sample size (n=13) of healthy men only, limiting generalizability. The 2-week treatment period is short and does not capture long-term effects. The study lacked a placebo control group. Only healthy men were studied; effects in populations with GH deficiency, obesity, or HIV lipodystrophy (the approved indication) may differ. Pulse frequency was not significantly affected, only pulse amplitude and basal secretion.